IP Library Granted Patent US 12,642,855
Granted Patent B2
US 12,642,855 · App. 19/083,391 · Granted Jun 2, 2026

Olfactory delivery scaffold compounds

Inventors: Kelvin Cooper (Sarasota, FL); Parnian Lak (Mountain View, CA); Renaud Renault (Emeryville, CA)
Assignee: Olfera Corporation
A61K47/543A61K9/0043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,642,855
App. No.
19/083,391
Granted
Jun 2, 2026
Kind
B2
Abstract

Exemplary olfactory delivery scaffolds may include 1) an olfactory targeting component, stimulant, or odorant that is recognized by the olfactory nerves via, for example, a smell response, 2) a molecule with biological activity, a therapeutic component, and/or drug (sometimes collectively referred to herein as a “therapeutic component”), and 3) a linker component that links the olfactory targeting component and therapeutic component together. The olfactory delivery scaffolds may be used to deliver a molecule with biological activity and/or a therapeutic component to a subject's neurological system through the olfactory pathway and pharmaceutical compositions useful in the treatment of neurological and/or neurodegenerative diseases.

Claims (14)

1 . A compound of Formula (D):

wherein,

R 1 R 2 N is selected from the group consisting of:

R 4 is H or C 1 -C 8 alkyl; and

R 3 is selected from the group consisting of:

2 . The compound of claim 1 , wherein the compound is

3 . The compound of claim 1 , wherein R 1 R 2 N is

4 . The compound of claim 1 , wherein R 1 R 2 N is

5 . The compound of claim 1 , wherein R 3 is

6 . The compound of claim 1 , wherein R 3 is

7 . The compound of claim 1 , wherein R 3 is

8 . The compound of claim 1 , wherein R 3 is

9 . The compound of claim 1 , wherein R 3 is

10 . A pharmaceutical composition for intranasal administration comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2026
From: RENAULT, RENAUD
To: OLFERA CORPORATION
Reel/Frame 074146/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2026
From: RENAULT, RENAUD
To: OLFERA CORPORATION
Reel/Frame 073852/0723 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2026
From: LAK, PARNIAN
To: OLFERA CORPORATION
Reel/Frame 073553/0827 →
Continuity (3)
Continuation PCTUS2024052459 · Oct 22, 2024
Provisional Application 63546506 · Oct 30, 2023
Related Publication 20250249106A1 · Aug 7, 2025
References Cited (17)
US 8299062B2 · Volvovitz · 2012 [cited by applicant]
US 20140364330A1 · Mershin et al. · 2014 [cited by applicant]
US 20190055511A1 · Villard et al. · 2019 [cited by applicant]
US 20200392490A1 · Ziv et al. · 2020 [cited by applicant]
US 20210113558A1 · Gendelman · 2021 [cited by examiner]
US 20220340849A1 · Pediaditakis et al. · 2022 [cited by applicant]
US 20250269038A1 · Cooper et al. · 2025 [cited by applicant]
WO 2005102275A2 · 2005 [cited by applicant]
WO 2018237302A1 · 2018 [cited by applicant]
WO 2022239001A1 · 2022 [cited by applicant]
WO 2025076268A1 · 2025 [cited by applicant]
WO 2025096244A1 · 2025 [cited by applicant]
Sarukhanyan et al. ACS Omega (2018), 3(5), 5281-5290. [cited by examiner]
International Search Report from Appl. No. PCT/US2024/052459, mailed on Jan. 31, 2025. [cited by applicant]
Kuhns et al., Characterizing novel olfactory receptors expressed in the murine renal cortex, Am J Physiol Renal Physiol, (2019), 317:F172-F186. [cited by applicant]
Office Action from U.S. Appl. No. 19/083,361, mailed on Sep. 26, 2025. [cited by applicant]
Ertural et al., RNA Therapeutics: Focus on Antisense Oligonucleotides in the Nervous System, Biomol Ther, (2025), 33:572-581. [cited by applicant]